Navigation Links
New study shows why swine flu virus develops drug resistance
Date:5/29/2012

Professor Adrian Mulholland and Dr Christopher Woods from Bristol's School of Chemistry, together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza commonly known as 'swine flu'.

Their results, published today [29 May] in Biochemistry, provide new insight that could lead to the development of the next generation of antiviral treatments for flu.

H1N1-2009 is a new, highly adaptive virus derived from different gene segments of swine, avian, and human influenza. Within a few months of its appearance in early 2009, the H1N1-2009 strain caused the first flu pandemic of the 21st-century.

The antiviral drugs Relenza and Tamiflu, which target the neuraminidase (NA) enzyme, successfully treated the infection but widespread use of these drugs has led to a series of mutations in NA that reduce the drugs' effectiveness.

Clinical studies indicate that the double mutant of swine flu NA known as IRHY2 reduced the effectiveness of Relenza by 21 times and Tamiflu by 12,374 times that is, to the point where it has become an ineffective treatment.

To understand why the effectiveness of Relenza and Tamiflu is so seriously reduced by the occurrence of this mutation, the researchers performed long-timescale molecular dynamics (MD) simulations using GPUs.

Professor Mulholland said: "Our simulations showed that IRHY became resistant to Tamiflu due to the loss of key hydrogen bonds between the drug and residues in a part of the NA's structure known as the '150-loop'.

"This allowed NA to change from a closed to an open conformation. Tamiflu binds weakly with the open conformation due to poor electrostatic interactions between the drug and the active site, thus rendering the drug ineffective."

These findings suggest that drug resistance could be overcome by increasing hydrogen bond interactions between NA inhibitors and residues in the 150-loop, with the aim of maintaining the closed conformation.


'/>"/>

Contact: Philippa Walker
philippa.walker@bristol.ac.uk
University of Bristol
Source:Eurekalert

Related medicine news :

1. STeleR study: Telerehab improves functioning after stroke
2. Night Shift Might Boost Womens Breast Cancer Risk: Study
3. 1 size doesnt fit all when treating blood pressure in people with diabetes, VA/U-M study suggests
4. As Obesity Rates Rise, Cases of Kidney Stones Double: Study
5. Physical Education Is Good for Kids Grades, Study Finds
6. New prostate cancer screening guidelines face a tough sell, study suggests
7. Chemicals in PVC Flooring Can Be Absorbed Into Childrens Bodies: Study
8. First study to suggest that the immune system may protect against Alzheimers changes in humans
9. States Use Only Fraction of Tobacco Revenues to Fight Smoking, Study Finds
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. Surgical Residents Often Fatigued, Study Confirms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... to compare student test score performance for the 2015-16 school year across Wisconsin’s ... voucher programs. Though it highlights important patterns in student test score performance, the ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to ... of acute or chronic problems, I focus on preventative care with all my patients to ... have any questions, always feel free to contact my office and my trained staff will ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DALLAS , April 19, 2017 /PRNewswire/ ... that the first patients in Nashville ... in the Lower Esophageal Sphincter Stimulation for GERD (LESS ... device designed to provide long-term reflux control by restoring ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device ... markets with innovative and proprietary products, will release financial ... after the market close on Tuesday, May 2, 2017. ... call and webcast to discuss its financial results the ... p.m. Eastern Time (3:30 p.m. Central Time). Darin ...
Breaking Medicine Technology: